These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38262639)

  • 1. Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial.
    Wen F; Lin T; Zhang P; Zeng H; Wei Q; Shen Y
    BMJ Open; 2024 Jan; 14(1):e076663. PubMed ID: 38262639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
    Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
    BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer.
    Jamil ML; Deebajah M; Sood A; Robinson K; Rao K; Sana S; Alanee S
    BMJ Open; 2019 Jul; 9(7):e028287. PubMed ID: 31320352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
    Petrausch U; Spahn M; Schneider M; Hayoz S; Rentsch CA; Rothschild S; Omlin A; Cathomas R
    BMJ Open; 2023 Jun; 13(6):e067634. PubMed ID: 37286312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial.
    Achard V; Fournier B; D'Haese D; Krzystyniak J; Tombal B; Roupret M; Sargos P; Dirix P
    Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38556413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Inman BA; Hahn NM; Stratton K; Kopp R; Sankin A; Skinner E; Pohar K; Gartrell BA; Pham S; Rishipathak D; Mariathasan S; Davarpanah N; Carter C; Steinberg GD
    Eur Urol Oncol; 2023 Jun; 6(3):313-320. PubMed ID: 36803840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    Gore JL; Wolff EM; Comstock BA; Follmer KM; Nash MG; Basu A; Chisolm S; MacLean DB; Lee JR; Lotan Y; Porten SP; Steinberg GD; Chang SS; Gilbert SM; Kessler LG; Smith AB;
    BMC Cancer; 2023 Nov; 23(1):1127. PubMed ID: 37980511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study.
    Jamil ML; Deebajah M; Sood A; Alanee S
    BMJ Open; 2019 Dec; 9(12):e027066. PubMed ID: 31796469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
    Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
    Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
    Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial.
    Arthuso FZ; Fairey AS; Boulé NG; Courneya KS
    BMJ Open; 2021 Sep; 11(9):e055782. PubMed ID: 34561265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
    Moe A; Liow E; Redfern A; Swarbrick N; Ferguson T; Davis ID; Hayne D
    BJU Int; 2021 Oct; 128 Suppl 1():9-17. PubMed ID: 33960102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.